Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 7/20 | 0.73 |
| ▸ | STAT6 | P42226 | 2/20 | 0.73 |
| ▸ | DPP4 | P27487 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.73 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.73 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.73 |
| ▸ | GAPDH | P04406 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.73 |
| ▸ | PI4KA | P42356 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.73 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.73 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.73 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272122 | 1.00 | SLC29A1 (0.73) | SLC29A1STAT6DPP4MEN1SLC28A1 | |
| SCHEMBL1858029 | 1.00 | SLC29A1 (0.73) | SLC29A1STAT6DPP4MEN1SLC28A1 | |
| SCHEMBL19443159 | 1.00 | SLC29A1 (0.73) | SLC29A1STAT6DPP4MEN1SLC28A1 | |
| SCHEMBL278513 | 1.00 | SLC29A1 (0.73) | SLC29A1STAT6DPP4MEN1SLC28A1 | |
| SCHEMBL67126 | 1.00 | SLC29A1 (0.73) | SLC29A1STAT6DPP4MEN1SLC28A1 | |
| SCHEMBL10062644 | 1.00 | SLC29A1 (0.73) | SLC29A1STAT6DPP4MEN1SLC28A1 | |
| SCHEMBL272123 | 1.00 | SLC29A1 (0.73) | SLC29A1STAT6DPP4MEN1SLC28A1 | |
| SCHEMBL10340725 | 1.00 | SLC29A1 (0.73) | SLC29A1STAT6DPP4MEN1SLC28A1 | |
| SCHEMBL21139429 | 1.00 | SLC29A1 (0.73) | SLC29A1STAT6DPP4MEN1SLC28A1 | |
| SCHEMBL91050 | 1.00 | SLC29A1 (0.73) | SLC29A1STAT6DPP4MEN1SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718853-B2 | Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-YL)-3,4-dihydroxytetrahydrofuran-2-YL)] methyl nitrate and processes of preparation thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2017-08-01 | — | — | US | disclosed |
| US-20120195827-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | GILEAD SCIENCE, INC. | 2012-08-02 | — | — | US | disclosed |
| US-8133879-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100292135-A1 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-11-18 | — | — | US | disclosed |
| US-20100183503-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | GILEAD PALO ALTO, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100081810-A1 | C-Pyrazole A2A Receptor Agonists | CV THERAPEUTICS, INC. | 2010-04-01 | — | — | US | disclosed |
| US-7683037-B2 | A2A receptor agonist; regadenoson (CVT-3146); produces coronary vasodilation without significant peripheral vasodilation; | GILEAD PALO ALTO, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7553823-B2 | C-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183503-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | ADORA2A, ADORA3, ADORA1 | SLC29A1 46/4885STAT6 2249/4885DPP4 1320/4885 |
| US-20100292135-A1 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | RECQL, DNA2, WRN | SLC29A1 1713/4885STAT6 4628/4885DPP4 3595/4885 |
| US-20100081810-A1 | C-Pyrazole A2A Receptor Agonists | ADORA2A, ADORA3, TBXA2R | SLC29A1 379/4885STAT6 1503/4885DPP4 1901/4885 |
| US-20120195827-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | ADORA2A, ADORA3, ADORA1 | SLC29A1 46/4885STAT6 2249/4885DPP4 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.